CAS 53-84-9 99% Anti-Aging Nad+ IV Nad Reta Cagrilintide
126 Inquiries
53-84-9
Pharmaceutical Grade
99%
ShenZhen
DL
100mg 500mg / vial ,10vials/box
Yes
2027-08-30
Tirzepatide,Retatrutide,Semaglutide
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceNAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
Solid
NAD zwitterion is a NAD. It has a role as a geroprotector. It derives from a deamido-NAD zwitterion. It is a conjugate base of a NAD(+).|A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)|Nadide is a dinucleotide of adenine and nicotinamide. It has coenzyme activity in redox reactions and also acts as a donor of ADP-ribose moieties.Basic Info-
Product Name:
NAD
Other Name:Adenosine 5′-(trihydrogen diphosphate),P′→5′-ester with 3-(aminocarbonyl)-1-β-D-ribofuranosylpyridinium,inner salt;Pyridinium,3-carbamoyl-1-β-D-ribofuranosyl-,hydroxide,5′→5′-ester with adenosine 5′-(trihydrogen pyrophosphate),inner salt;Adenosine 5′-(trihydrogen diphosphate),P′→5′-ester with 3-(aminocarbonyl)-1-β-D-ribofuranosylpyridinium hydroxide,inner salt;Codehydrase I;Codehydrogenase I;Coenzyme I;Diphosphopyridine nucleotide;DPN;Cozymase I;NAD;Nadide;Nicotinamide-adenine dinucleotide;Oxidized diphosphopyridine nucleotide;Adenine-nicotinamide dinucleotide;NAD+;Enzopride;β-NAD;β-Diphosphopyridine nucleotide;β-Nicotinamide adenine dinucleotide;β-NAD+;NSC 20272;CO-I;β-Nicotinamide adenine dinucleotide hydrate;30429-30-2;159929-29-0;1083039-67-1;1354693-98-3
CAS No.:53-84-9
Molecular Formula:C21H27N7O14P2
InChIKeys:InChIKey=BAWFJGJZGIEFAR-NNYOXOHSSA-N
Molecular Weight:663.43
Exact Mass:663.109131
EC Number:200-184-4
NSC Number:757121
DSSTox ID:DTXSID2045236
NCI Thesaurus Code:C87339
HScode:29349990
Categories:
Characteristics-
PSA:
321
XLogP3:-1.29620
Appearance:White Powder
Melting Point:140-142 °C (decomp)
Water Solubility:soluble in water at 50mg/ml
Storage Conditions:2-8°C
Specific rotation:D20 -31.5° (c = 1.2 in water)
Collision Cross Section:226.7 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]|227.5 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|222.7 Ų [M+Na]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|223.8 Ų [M-H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|230.8 Ų [M+Na-2H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|227 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]
Research-
Class:
Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)
Status:Investigational — Phase 3 (REDEFINE program, CagriSema combination)
Mechanism:A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity.
Activity note:Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.
Source:MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.
Clinical Development:
References-
PubChem:Literature:
MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation
Disclaimer:Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Hazard IdentificationClassification of the substance or mixture
Not classified.
GHS label elements, including precautionary statements
Pictogram(s) No symbol. Signal word No signal word
Hazard statement(s) none
Precautionary statement(s) Prevention none
Response none
Storage none
Disposal none
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,Semaglutide
-
Location:
Room 1811-A096, Jingu Building, No.319 Jinxing Middle Road, Xihu Street, Yuelu District, Changsha City, Hunan Province
-
Payment Terms:
TT against copy of documents
-
Average lead Time:
2 days
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2023
-
-
Inquiry History126 Inquiries
Country Product Purchase Quantity Date Posted
United States
NAD
1 KG Oct 26, 2026
India
NAD
100 G Oct 21, 2026
India
NAD+
20 G Sep 30, 2026
United States
NAD
30 MT Sep 29, 2026
United Arab Emirates
NAD
10 MT Sep 19, 2026
Australia
NAD
50 PCS Sep 16, 2026
United States
NAD
30 MG Sep 1, 2026
Philippines
NAD+
15 KG Sep 1, 2026
Philippines
NAD+
15 KG Aug 31, 2026
United Kingdom
NAD+ 500mg for IV therapy
2 MG Aug 11, 2026
United States
NAD+
1 G Aug 7, 2026
United States
NAD+ 500mg / 1000mg
100 MG Aug 7, 2026
United States
NAD+
1000 MG Aug 4, 2026
South Africa
Nad+
10 MT Jul 27, 2026
United States
β-Nicotinamide adenine dinucleotide
10 G Jul 16, 2026
Poland
Fenbendazole
1 KG Jul 14, 2026
United States
NAD
10 MT Jul 9, 2026
United States
NAD+ 500
10000 MG Jul 2, 2026
United States
Beta-Nicotinamide adenine dinucleotide Nad+
1 MG Jun 18, 2026
Australia
Nad
10 MG Jun 16, 2026 Post an enquiry for this product
More from this Seller
-
-
-
Tirzepatide 2023788-19-2 99% White powder High Quality tirzepatide weight loss
Pharmaceutical Grade / 99%
-
-
-
-
SS-31 High Quality SS-31 99% Purity Factory direct sales, available in stock
Pharmaceutical Grade / 99%
$120-130/UNIT FOB
-
-
-
-
Fast Shipping 99% Purity Raw Powder Mazdutide Peptides for Effective Weight Loss Customize Peptide
Pharmaceutical Grade / 99%
-
-
-
-
High-quality Antibacterial Peptide BAC in 10ml Bottled Water, 99% Content, Pharmaceutical Grade
Pharmaceutical Grade / 99%
$11.76-14.7/UNIT FOB
-
-
-
-
Weight Managemet Raw Survodutide Retatrutide Tirzepatide Powder Peptide Fast delivery
Pharmaceutical Grade / 99%
$100-110/UNIT FOB
-
Hot Related Products
-
Βeta-Nicotinamide Mononucleotide -
Nicotinamide mononucleotide high pure 99% raw material powder CAS 1094-61-7 -
β-Nicotinamide Mononucleotide -
Beta-Nicotinamide Mononucleotide -
β-Nicotinamide Mononucleotide CAS 1094-61-7 99% High Purity White Powder Hot Sale Pharmaceutical Best Service$2.52/KG FOB
-
β-Nicotinamide Mononucleotide 1094-61-7 high purity -
β-Nicotinamide mononucleotide 98% white Powder staherb staherb -
NMN / β-Nicotinamide Mononucleotide -
β-Nicotinamide Mononucleotide cas 1094-61-7 White to slightly yellow crystalline powder Research and development of customized synthesis -
β-Nicotinamide Mononucleotide,NMN 99% powder CAS No.1094-61-7
